Control of cytomegalovirus retinitis after combination antiretroviral therapy. NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Control of cytomegalovirus retinitis after combination antiretroviral therapy.

Acta Ophthalmol Scand. 1999 Aug;77(4):471-3. Unique Identifier : AIDSLINE MED/99391067
Ruhswurm I; Ries E; Krepler K; Derbolav A; Rieger A; Armbruster C; Wedrich A; Department of Ophthalmology, University of Vienna, Medical; School, Austria.

Abstract: PURPOSE: To report on AIDS patients having combination antiretroviral therapy whose cytomegalovirus (CMV) retinitis remained inactive after discontinuation of anti-CMV maintenance therapy. METHODS: We describe the course of CMV-retinitis in 3 patients with AIDS after initiation of combination antiretroviral therapy. RESULTS: After cessation of anti-CMV therapy no relapse of CMV-retinitis has been observed for up to 18 months. Two of the patients developed new CMV-retinitis in the first months after initiation of combination therapy, nevertheless after further improvement of immunological parameters retinitis remained stable without anti-CMV therapy. CONCLUSION: The sustained immunological effects of combination therapy are possibly sufficient enough to provide protection against CMV-retinitis.
Keywords: JOURNAL ARTICLE Adult Anti-HIV Agents/*THERAPEUTIC USE AIDS-Related Opportunistic Infections/COMPLICATIONS/IMMUNOLOGY/ *PREVENTION & CONTROL Case Report Cytomegalovirus Retinitis/COMPLICATIONS/IMMUNOLOGY/*PREVENTION & CONTROL CD4 Lymphocyte Count Drug Therapy, Combination Follow-Up Studies Ganciclovir/*THERAPEUTIC USE Human HIV/GENETICS Indinavir/*THERAPEUTIC USE Male Middle Age RNA, Viral/ANALYSIS Saquinavir/*THERAPEUTIC USEKWDjournalarticleadultanti-hivagents/KWDtherapeuticuseaids-relatedopportunisticinfections/complications/immunology/KWDprevention&controlcasereportcytomegalovirusretinitis/complications/immunology/KWDprevention&controlcd4lymphocytecountdrugtherapy,combinationfollow-upstudiesganciclovir/KWDtherapeuticusehumanhiv/geneticsindinavir/KWDtherapeuticusemalemiddleagerna,viral/analysissaquinavir/KWDtherapeuticuse
991230
A99C1017

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .